Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 2, 2026
Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Fineline Cube Mar 2, 2026
Company Drug

Yiling Pharmaceutical Gains NMPA Approval for XY0206 in AML Trial

Fineline Cube Oct 24, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...

Company Drug

Chengdu Kanghong Receives FDA Nod for Clinical Trial of Novel Depression Therapy KH607

Fineline Cube Oct 24, 2023

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced that it has received...

Company Medical Device

Blue Sail Medical Enrolls First Patient in Study for Rapamycin-Coated Balloon Catheter

Fineline Cube Oct 24, 2023

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced a significant milestone with the...

Company Drug

Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO

Fineline Cube Oct 24, 2023

China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...

Company Drug

Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment

Fineline Cube Oct 24, 2023

China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...

Company Deals

Roche Agrees to Acquire Telavant for $7.1 Billion to Boost IBD Treatment Portfolio

Fineline Cube Oct 24, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) announced this week an agreement to purchase Telavant Holdings,...

Company Deals

J&J MedTech Partners with CED Medical for Neurointerventional Solutions

Fineline Cube Oct 24, 2023

Johnson & Johnson MedTech’s (J&J, NYSE: JNJ) Shanghai-based subsidiary, Johnson Johnson Medical Equipment Co., Ltd,...

Company Drug

Alphamab Oncology Presents Promising Data for KN046 and KN026 at ESMO 2023

Fineline Cube Oct 24, 2023

China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of...

Company Drug

Janssen’s TAR-200 Shows High Complete Response Rate in Bladder Cancer Study

Fineline Cube Oct 23, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has published data from a Phase IIb...

Company Drug

Novartis’ Kisqali Plus Endocrine Therapy Shows Improved Survival in Early Breast Cancer Study

Fineline Cube Oct 23, 2023

Switzerland-based pharmaceutical company Novartis (NYSE: NVS) has announced additional results from an ongoing Phase III...

Company

Boehringer Ingelheim Appoints Mohammed Tawil as New CEO for Greater China Region

Fineline Cube Oct 23, 2023

Germany’s Boehringer Ingelheim (BI) has announced a leadership transition within its Greater China region, which...

Company Drug

Pfizer’s Penbraya Receives FDA Approval for Meningococcal Immunization

Fineline Cube Oct 23, 2023

Pfizer Inc. (NYSE: PFE) announced last week that it has successfully registered its pentavalent meningococcal...

Policy / Regulatory

National VBP Tender Program Invites Drugs Approved Before October 30 for Round 9

Fineline Cube Oct 23, 2023

The National Allied Procurement Office has released a notification regarding Round 9 of the national...

Company Deals

MSD Cancels Development of Two Pre-Clinical ADCs from Sichuan Kelun-Biotech

Fineline Cube Oct 23, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its innovative drug development subsidiary Sichuan...

Company Drug

Health Canada Approves Pfizer and Sumitomo Pharma’s Myfembree for Endometriosis Pain Management

Fineline Cube Oct 23, 2023

Health Canada has granted regulatory approval to Pfizer (NYSE: PFE) and Sumitomo Pharma (TYO: 4506)...

Company

Shanghai Henlius Receives GMP Certification from ANVISA for Biosimilar Manufacturing

Fineline Cube Oct 23, 2023

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Henlius Biotech,...

Company Drug

Shanghai Fudan-Zhangjiang’s ADC FZ-AD005 Accepted for NMPA Review in Advanced Solid Tumors

Fineline Cube Oct 23, 2023

China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the National...

Company Deals

AcuVu Medical Partners with Hologic for US Distribution of HummingScope Hysteroscopy System

Fineline Cube Oct 23, 2023

AcuVu Medical, a specialist in electronic endoscopes with operations in California, USA, and Suzhou, China,...

Company Deals

CBC HIP Secures USD 875 Million for Life Science Real Assets Venture CLSRA

Fineline Cube Oct 23, 2023

CBC Healthcare Infrastructure Platform (CBC HIP), a prominent independent life science real assets investor in...

Company Drug

BeiGene’s Brukinsa Gains NICE Recommendation for CLL Treatment in the UK

Fineline Cube Oct 23, 2023

China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National...

Posts pagination

1 … 418 419 420 … 628

Recent updates

  • Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy
  • HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline
  • Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.